Open AccessFunctional Characterization of Human Stem Cell–Derived Cardiomyocytes
Author(s) -
Kirsch Glenn E.,
ObejeroPaz Carlos A.,
BrueningWright Andrew
Publication year - 2000
Publication title -
current protocols in pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 26
eISSN - 1934-8290
pISSN - 1934-8282
DOI - 10.1002/0471141755.ph1112s64
Subject(s) - drug discovery , pharmacology , cell , drug , electrophysiology , medicine , neuroscience , computational biology , bioinformatics , biology , biochemistry
Cardiac toxicity is a leading contributor to late stage attrition in the drug discovery process and to withdrawal of approved drugs from the market. In vitro assays that enable earlier and more accurate testing for cardiac risk provide early stage predictive indicators that aid in mitigating risk. Human cardiomyocytes, the most relevant subjects for early stage testing, are severely limited in supply, but human stem cell–derived cardiomyocytes (SC‐hCM) are readily available from commercial sources and are increasingly used in academic research, drug discovery, and safety pharmacology. As a result, SC‐hCM electrophysiology has become a valuable tool for assessing cardiac risk associated with drug administration. Described in this unit are techniques for recording individual sodium, calcium, and potassium currents, as well as single‐cell action potentials and impedance recordings from contracting syncytia of thousands of interconnected cells. Curr. Protoc. Pharmacol . 64:11.12.1‐11.12.26. © 2014 by John Wiley & Sons, Inc.